NumFin

Cosmo Pharmaceuticals N.V.

Sümbol: COPN.SW

SIX

71.4

CHF

Turuhind täna

  • 1009.1513

    P/E suhe

  • 14.6994

    PEG suhe

  • 1.15B

    MRK Cap

  • 0.01%

    DIV tootlus

Cosmo Pharmaceuticals N.V. (COPN-SW) Finantsaruanded

Download
AastaneQuarterly
LineaarneLog
Diagrammil näete Cosmo Pharmaceuticals N.V. (COPN.SW) vaikimisi numbreid dünaamikates. Companys revenue näitab keskmist NaN M, mis on NaN % gowth. Kogu perioodi keskmine brutokasum on NaN M, mis on NaN %. Keskmine brutokasumi suhtarv on NaN %. Ettevõtte eelmise aasta tulemuse puhaskasv on NaN %, mis on võrdne NaN % % keskmiselt kogu ettevõtte ajaloo jooksul.,

AastaneQuarterly
10Y20Y30Y40Y

Bilanss

Sukeldudes Cosmo Pharmaceuticals N.V. fiskaalkäiguteele, täheldame keskmist varade kasvu. See määr on huvitaval kombel , mis kajastab nii ettevõtte kõrg- kui ka madalseisusid. Kui võrrelda kvartalite lõikes, siis kohandub see näitaja . Kui vaadata tagasi möödunud aastale, siis on varade kogumuutus NaN. Aktsionäride väärtus, mida näitab aktsionäride kogu omakapital, on hinnatud NaN aruandlusvaluutas. Selle aspekti aastane muutus on NaN%.

common:word.in-mln

USD
Growth
TTM20232022202120202019201820172016201520142013201220112010200920082007200620052004

balance-sheet.row.cash-and-short-term-investments

050.3241222.2
212.9
268.2
349.4
172.7
166.5
116.3
59.5
168.2
27.3
13.6
28.5
17.3
22.2
25.5
1.1
0.7
0.3

balance-sheet.row.short-term-investments

0055.123.6
26.9
157.8
138.7
27.8
48.8
45.1
25.3
121.8
0
0
0.1
0.1
0
0
0
0
0

balance-sheet.row.net-receivables

028.538.624.5
27
19.1
0
0
0
0
0
0
0
0
0
0
0.6
0
0
0
0

balance-sheet.row.inventory

014.211.513.1
5.7
6.1
3.9
3.2
2.3
2.2
3.3
2.9
2.2
1.8
1.3
1.5
1.5
1.5
1
1.3
1

balance-sheet.row.other-current-assets

09.353.639.7
34.2
166.8
0
21.4
18.3
19.3
7.9
17.3
10.5
13.1
13.7
11
9.4
6.6
7.9
6.3
2.8

balance-sheet.row.total-current-assets

0102.2306.1275.8
252.9
302.4
374.2
197.3
187.1
137.9
70.7
188.3
40
28.6
43.4
29.8
33.7
33.7
10
8.3
4.1

balance-sheet.row.property-plant-equipment-net

028.630.330.5
29.3
30.2
28.6
30.2
20.7
21.1
21.4
21.7
22.2
6
6.4
6.8
7
6.9
7.1
13
9.6

balance-sheet.row.goodwill

0242424
1.4
1.4
1.4
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1

balance-sheet.row.intangible-assets

0355.6366.8372.7
26.6
49.2
35.5
28.5
19.5
4.5
10.3
16.3
22.2
22
20.4
12
6.9
3.2
3.4
0.9
0.9

balance-sheet.row.goodwill-and-intangible-assets

0379.6390.8396.7
28.1
50.7
37
28.6
19.7
4.6
10.4
16.5
22.3
22.1
20.5
12.1
7
3.3
3.5
1
1.1

balance-sheet.row.long-term-investments

03.3-46.925.4
223.7
21.6
33.5
201.8
164.7
227.2
95.5
-106.3
0
0
18.1
19.1
2.1
0
0
0
0

balance-sheet.row.tax-assets

0014.718.6
8.2
10
11.7
10.5
2.6
2.1
2.2
1
1.3
0.8
1
1.2
1.2
1.4
1.1
1.5
0.7

balance-sheet.row.other-non-current-assets

040.364.558.4
54
170.3
140.7
29.6
48.8
45.1
25.3
121.8
66.1
20.6
2.3
2.3
6.8
2
1.9
4.4
8

balance-sheet.row.total-non-current-assets

0451.8453.5529.7
343.3
282.8
251.5
300.7
256.4
300
154.9
54.7
111.9
49.4
48.4
41.6
24.1
13.6
13.6
19.9
19.3

balance-sheet.row.other-assets

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-assets

0554759.6805.6
596.2
585.2
625.7
498
443.5
437.9
225.6
243
151.8
78
91.8
71.5
57.8
47.2
23.6
28.2
23.5

balance-sheet.row.account-payables

08.810.711.6
8.4
7.8
8.8
11.3
6.1
4.3
5.5
4.2
4
4.1
5.6
4.1
1.2
4.9
4.7
3.4
3.1

balance-sheet.row.short-term-debt

00.1171.80.9
2.9
1.5
0.5
0.6
0.8
1.6
2
2
1.8
0.9
1.3
1.3
1.4
1.5
3.9
7.7
4.1

balance-sheet.row.tax-payables

002.73.6
2.8
0.5
0.4
1.5
2.8
0.5
33.3
2
5.3
0.4
0.3
0.5
0.6
0.2
0.6
0.5
0.3

balance-sheet.row.long-term-debt-total

00.91.8169
165.2
163.3
157.6
3.8
4.5
6.6
8.9
9.8
11
1.3
2.2
1.6
2.9
0
4.8
13.9
15.3

Deferred Revenue Non Current

0000.5
0.4
0.3
-155.8
3.9
-1.9
-3
-4.8
-6.6
-8.7
1.1
1.1
1.6
-2
0
2.6
-3.5
-8.6

balance-sheet.row.deferred-tax-liabilities-non-current

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

balance-sheet.row.other-current-liab

014.312.53.2
7
5.2
6
5.1
8.4
18.3
5.8
1.1
1
5.3
20.3
1.8
6.2
0.2
3
1.1
0.5

balance-sheet.row.total-non-current-liabilities

097.2100.9271.6
174.2
175.7
165.5
8.4
9.2
9.3
12.7
13.2
14.9
4.3
6.2
4.4
5.1
5.5
6.7
15.4
16.6

balance-sheet.row.other-liabilities

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.capital-lease-obligations

01.322.6
5
5.6
2.6
3
3.8
6.6
8
9.3
9.8
0
0
0
0
0
2.6
8
6.6

balance-sheet.row.total-liab

0120.3295.8292.9
196
191.4
180.8
27.9
27.9
34.3
73.3
22.8
27.2
14.6
33.5
11.7
14.5
12.1
18.3
27.6
24.3

balance-sheet.row.preferred-stock

0011.518.4
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.common-stock

04.64.64.6
3.9
3.9
3.9
3.9
3.7
3.7
3.7
3.7
3.7
3.7
3.7
3.5
3.5
3.5
2.5
2.5
2.3

balance-sheet.row.retained-earnings

0302.6262.2293.3
265.4
272.4
300
319.6
372.6
372.9
127
107.6
36
17.2
17.2
9.5
0.1
0.1
-4.6
-4.7
-3.9

balance-sheet.row.accumulated-other-comprehensive-income-loss

0-22.7-11.5-18.4
95.8
76.6
0
-26.3
-23.7
-21.6
-19.5
-17.2
-14.7
-9.7
-8.2
-6.8
0
0
0
0
0

balance-sheet.row.other-total-stockholders-equity

0142.3190.1207.4
35
40.8
139.8
172.9
62.9
48.5
41
126
99.4
52
45.3
53.6
39.7
31.6
7.4
2.7
0.7

balance-sheet.row.total-stockholders-equity

0426.8456.9505.3
400.1
393.7
443.8
470.1
415.5
403.6
152.3
220.1
124.4
63.2
58.1
59.8
43.2
35.1
5.3
0.6
-0.9

balance-sheet.row.total-liabilities-and-stockholders-equity

0554759.6805.6
596.2
585.2
625.7
498
443.5
437.9
225.6
243
151.8
78
91.8
71.5
57.8
47.2
23.6
28.2
23.5

balance-sheet.row.minority-interest

06.96.97.4
0
0
1.1
0
0
0
0
0
0.2
0.2
0.3
0
0
0
0
0
0

balance-sheet.row.total-equity

0433.6463.8512.7
400.1
393.7
444.9
-
-
-
-
-
-
-
-
-
-
-
-
-
-

balance-sheet.row.total-liabilities-and-total-equity

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

Total Investments

03.38.349.1
250.6
179.5
172.3
229.6
213.5
272.2
120.8
15.5
66.1
18.3
18.2
19.2
2.1
0
0
0.1
0.1

balance-sheet.row.total-debt

01.1173.6169.9
168.1
164.8
158.2
4.5
5.3
8.1
10.9
11.7
12.8
2.2
3.5
3
4.3
1.5
8.7
21.6
19.3

balance-sheet.row.net-debt

0-49.2-12.2-28.6
-17.8
54.5
-52.5
-140.5
-112.3
-63.1
-23.2
-34.6
-14.5
-11.4
-24.9
-14.2
-17.9
-24
7.6
20.9
19.1

Rahavoogude aruanne

Cosmo Pharmaceuticals N.V. finantsmaastikul on viimase perioodi jooksul toimunud märkimisväärne muutus vabas rahavoos, mis näitab NaN nihet. Ettevõte laiendas hiljuti oma aktsiakapitali, emiteerides NaN, mis tähistab NaN erinevust võrreldes eelmise aastaga. Ettevõtte investeerimistegevuse tulemusel kasutas ettevõte netosularaha, mis aruandlusvaluutas oli NaN. See on NaN nihkumine võrreldes eelmise aastaga. Samal perioodil registreeris ettevõte NaN, NaN, NaN, mis on olulised ettevõtte investeerimis-ja tagasimaksestrateegiate mõistmiseks. Ettevõtte finantseerimistegevuse tulemusel kasutas ettevõte netorahavahendeid NaN, kusjuures erinevus võrreldes eelmise aastaga oli NaN. Lisaks eraldas ettevõte NaN aktsionäridele dividendide maksmiseks. Samal ajal tegi ta muid finantsmanöövreid, millele viidatakse kui NaN, mis samuti mõjutasid oluliselt tema rahavooge sel perioodil. Need komponendid koos annavad tervikliku pildi ettevõtte finantsseisundist ja strateegilisest lähenemisest rahavoogude juhtimisele.

common:word.in-mln

USD
Growth
TTM2022202120202019201820172016201520142013201220112010200920082007200620052004

cash-flows.row.net-income

024.524-6.9
-21.3
-17.5
-32.4
27.5
254.3
108.9
71.7
26.9
9.1
4.5
5.3
9.4
0.1
0.8
1.3
-1.2

cash-flows.row.depreciation-and-amortization

013.97.46
0
4.5
3.5
3
8.5
8.8
8.9
2.5
2.2
2
1.7
1.6
1.5
1.5
0.9
0.8

cash-flows.row.deferred-income-tax

00-21.45.9
9.3
0
13.3
-3.7
-294.4
-66
-65.7
-2.5
0
-0.1
0
0
0
0
0
0

cash-flows.row.stock-based-compensation

02.11.59
10.1
9.6
9.4
6.5
5.7
4.4
0
0
0
0.6
0
0
0
0
0
0

cash-flows.row.change-in-working-capital

0-13.3-5.1-5.1
-9
-3.5
-0.9
-6.7
-15.5
11.7
-5.9
-3.9
1.3
1.5
-2.8
-2.5
-3.6
3.7
-0.1
1

cash-flows.row.account-receivables

0-14.23.3-7.9
-3.7
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.inventory

01.6-6.10.4
-2.2
-0.7
-0.9
-0.1
1.1
-0.5
-0.7
-0.4
-0.5
0.2
0
0
-0.6
0.3
-0.3
-0.1

cash-flows.row.account-payables

014.2-3.37.9
3.7
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.other-working-capital

0-14.91-5.6
-6.8
-2.8
0
-6.7
-16.6
12.1
-5.3
-3.6
1.8
1.3
-2.8
-2.5
-3.1
3.4
0.2
1.1

cash-flows.row.other-non-cash-items

06.16.24.2
-7.9
-3.3
-3
-0.1
2.2
-1.2
-0.8
0.1
-1.3
-0.7
-0.3
-21
-0.4
0
-0.5
-0.3

cash-flows.row.net-cash-provided-by-operating-activities

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.investments-in-property-plant-an-equipment

0-7.3-8.5-8.1
-17.3
-9.7
-22
-18.4
-2.5
-2.5
-2.7
-3
-3.4
-7.4
-6.7
-5.4
-1.1
-8.1
-4.2
-2.4

cash-flows.row.acquisitions-net

0023.3-4.1
15.1
-0.1
-9.7
-16.6
111.5
-0.3
0.8
0
-2.3
6.3
0
0
0
0
0
0

cash-flows.row.purchases-of-investments

0-54-1-20
-89.8
-176
-68.4
-12.3
-134.6
-132.2
-67.3
-3
-0.1
-2.2
0
0
0
0
0
0

cash-flows.row.sales-maturities-of-investments

035.97.7131.6
68.2
111.2
64.2
71
104.5
123.1
66.8
0
0.6
9.5
0
0
0
0.1
0
0

cash-flows.row.other-investing-activites

027.13.3-23.9
-24.8
2.8
13.7
16.6
0.2
0.4
-0.8
0.1
2.3
-6.3
0
-9.3
2
12.3
0
0

cash-flows.row.net-cash-used-for-investing-activites

01.724.975.4
-48.7
-71.8
-22.3
40.2
78.9
-11.5
-3.2
-6
-2.8
-0.1
-6.7
-14.7
0.9
4.3
-4.2
-2.4

cash-flows.row.debt-repayment

0-0.9-2.6-1.8
-1.8
-0.7
-0.9
-3
-2.8
-2
-2.1
-1.4
-1.4
-2.1
-1.5
-0.8
0
-12.5
0
0

cash-flows.row.common-stock-issued

00.30.85.3
0
0
96.3
0
0.3
0
15.3
3.2
0
0
0
0
0
0
0.3
0

cash-flows.row.common-stock-repurchased

0-24.7-19.7-11
-25.3
-18.4
0
0
0
-52.1
0
0
0
-0.3
0
0
0
0
0
0

cash-flows.row.dividends-paid

0-15.6-0.80
0
0
-22.6
-19.7
0
-14.3
0
-1.2
0
0
0
0
0
0
0
0

cash-flows.row.other-financing-activites

0-5.1-4.9-4.4
-7.4
163.4
-0.2
0.1
0
1.3
1
-4
-21.8
5.8
-0.7
-0.4
26.6
4.8
0.6
2.3

cash-flows.row.net-cash-used-provided-by-financing-activities

0-46.1-27.2-11.9
-34.5
144.4
72.7
-22.6
-2.6
-67.1
14.1
-3.4
-23.2
3.4
-2.2
-1.2
26.6
-7.6
0.9
2.3

cash-flows.row.effect-of-forex-changes-on-cash

0-1.52.4-1
1.7
3.3
-13.1
2.3
0
0
0
0
0
0
0
25
0
0
0
0

cash-flows.row.net-change-in-cash

0-12.712.675.5
-100.3
65.7
27.3
46.4
37.1
-12.2
19
13.7
-14.7
11.2
-5
-3.3
25
2.7
-1.6
0.1

cash-flows.row.cash-at-end-of-period

0185.8198.6185.9
110.4
210.7
144.9
117.6
71.3
34.1
46.3
27.3
13.6
28.3
17.2
22.2
25.5
-0.7
-3.5
-1.8

cash-flows.row.cash-at-beginning-of-period

0198.6185.9110.4
210.7
144.9
117.6
71.3
34.1
46.3
27.3
13.6
28.3
17.2
22.2
25.5
0.5
-3.5
-1.8
-1.9

cash-flows.row.operating-cash-flow

033.212.613
-18.8
-10.2
-10
26.4
-39.2
66.4
8.1
23
11.3
7.8
3.9
-12.5
-2.5
6.1
1.7
0.3

cash-flows.row.capital-expenditure

0-7.3-8.5-8.1
-17.3
-9.7
-22
-18.4
-2.5
-2.5
-2.7
-3
-3.4
-7.4
-6.7
-5.4
-1.1
-8.1
-4.2
-2.4

cash-flows.row.free-cash-flow

025.94.14.9
-36.2
-19.8
-32
8
-41.8
63.9
5.4
20
7.9
0.4
-2.8
-17.9
-3.6
-2
-2.5
-2.2

Kasumiaruande rida

Cosmo Pharmaceuticals N.V. tulud muutusid võrreldes eelmise perioodiga NaN%. COPN.SW brutokasum on teatatud NaN. Ettevõtte tegevuskulud on NaN, mille muutus võrreldes eelmise aastaga on NaN%. Kulud amortisatsioonikulud on NaN, mis on NaN% muutus võrreldes eelmise aruandeperioodiga. Tegevuskulud on teatatud NaN, mis näitab NaN% muutust võrreldes eelmise aastaga. Müügi- ja turunduskulud on NaN, mis on NaN% muutus võrreldes eelmise aastaga. Hiljutistel numbritel põhinev EBITDA on NaN, mis tähendab NaN% kasvu võrreldes eelmise aastaga. Tegevustulu on NaN, mis näitab NaN% muutust võrreldes eelmise aastaga. Puhaskasumi muutus on NaN%. Eelmise aasta puhaskasum oli NaN.

common:word.in-mln

USD
Growth
TTM20232022202120202019201820172016201520142013201220112010200920082007200620052004

income-statement-row.row.total-revenue

096.7102.165.1
60.9
62.5
65.6
67.2
67.7
60.6
79.6
56.4
59.5
33.5
32
26.7
34.2
21.9
15.2
15.5
11

income-statement-row.row.cost-of-revenue

039.318.815.1
10.4
9.2
12.4
12.1
10.2
10.1
11.6
10.3
8.4
14.5
14.3
12.8
13.2
7
5.5
5.7
4.2

income-statement-row.row.gross-profit

057.483.349.9
50.5
53.2
53.2
55.1
57.5
50.5
68
46.1
51.1
19
17.7
13.9
21
14.9
9.7
9.8
6.9

income-statement-row.row.gross-profit-ratio

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.research-development

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-general-administrative

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-and-marketing-expenses

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-expenses

0051.736
39.1
55.7
51.6
0
0
0
0
0
0
0
0
0
0
0
0.2
0.3
0.5

income-statement-row.row.operating-expenses

045.355.338.8
43.6
65.6
69.9
64.7
32.1
56
45.8
33.1
24.7
10.1
12.9
9.5
9.8
14.7
11.5
8.5
7.6

income-statement-row.row.cost-and-expenses

084.77454
54
74.8
82.2
76.8
42.3
66
57.4
43.4
33.1
24.6
27.2
22.2
23
21.7
17
14.2
11.8

income-statement-row.row.interest-income

04.52.93.1
1.7
1
2.2
3
10.9
13.7
6.7
1.7
1
1
0.6
1.3
1.4
0.9
0
0
0

income-statement-row.row.interest-expense

009.29
8.7
8.5
0.6
0.1
0.1
0.2
0.2
0.3
0.1
0.8
1
0.4
0.9
0
0.9
0.8
0.6

income-statement-row.row.selling-and-marketing-expenses

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.total-other-income-expensenet

0-4.6-3.6-9.1
-9
-9
-0.8
-16.9
6.5
4
86.6
58.7
0.4
-0.8
-1
-0.4
-0.9
-0.1
2.4
-0.3
-0.6

income-statement-row.row.ebitda-ratio-caps

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-operating-expenses

0051.736
39.1
55.7
51.6
0
0
0
0
0
0
0
0
0
0
0
0.2
0.3
0.5

income-statement-row.row.total-operating-expenses

0-4.6-3.6-9.1
-9
-9
-0.8
-16.9
6.5
4
86.6
58.7
0.4
-0.8
-1
-0.4
-0.9
-0.1
2.4
-0.3
-0.6

income-statement-row.row.interest-expense

009.29
8.7
8.5
0.6
0.1
0.1
0.2
0.2
0.3
0.1
0.8
1
0.4
0.9
0
0.9
0.8
0.6

income-statement-row.row.depreciation-and-amortization

013.619.47.4
6
2.8
5.9
3.5
3
8.5
8.8
8.9
2.5
2.2
2
1.7
1.6
1.5
1.5
0.9
0.8

income-statement-row.row.ebitda-caps

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.operating-income

012.228.133.1
2.1
-12.3
-16.6
-15.5
21
250.3
22.2
12.9
26.5
9.9
5.4
5.7
12.6
0.2
-1.6
1.6
-0.6

income-statement-row.row.income-before-tax

07.624.524
-6.9
-21.3
-17.5
-32.4
27.5
254.3
108.9
71.7
26.9
9.1
4.5
5.3
11.6
0.2
0.8
1.3
-1.2

income-statement-row.row.income-tax-expense

06.372.3
1
3.2
0.6
0
8.2
6.1
35.5
2.9
7.6
1.5
0.9
1.3
2.2
0
0.9
0.5
1

income-statement-row.row.net-income

01.117.221.7
-7.9
-24.5
-18.1
-32.4
19.3
248.2
73.3
68.7
19.3
7.6
3.6
4
9.4
0.1
-0.1
0.8
-2.2
Sarnased aktsiad
Sind võib huvitada ka:
MARKSANS.NS
Marksans Pharma Limited.
156.1 INR
NSE
2186.HK
Luye Pharma Group Ltd..
3.04 HKD
HKSE
PTKFY
PT Kalbe Farma Tbk..
17.03 USD
PNK
VIRP.PA
Virbac SA.
334 EUR
EURONEXT
DSKYF
Daiichi Sankyo Company, Limited.
33.8 USD
PNK
ALPMF
Astellas Pharma Inc..
10.035 USD
PNK
NGLFINE.NS
NGL Fine-Chem Limited.
2128.05 INR
NSE
BMY
Bristol-Myers Squibb Company.
44.74 USD
NYSE
ORNBV.HE
Orion Oyj.
36.4 EUR
HEL
CHGCF
Chugai Pharmaceutical Co., Ltd..
32.43 USD
PNK
NVS
Novartis AG.
100.21 USD
NYSE

Korduma kippuv küsimus

Mis on Cosmo Pharmaceuticals N.V. (COPN.SW) koguvara?

Cosmo Pharmaceuticals N.V. (COPN.SW) koguvara on 553980000.000.

Mis on ettevõtte aastane tulu?

Aastane tulu on N/A.

Mis on ettevõtte kasumimarginaal?

Ettevõtte kasumimarginaal on 0.593.

Mis on ettevõtte vaba rahavoog?

Vaba rahavoog on 1.901.

Mis on ettevõtte puhaskasumimarginaal?

Puhaskasumimarginaal on 0.012.

Mis on ettevõtte kogutulu?

Kogutulu on 0.126.

Mis on Cosmo Pharmaceuticals N.V. (COPN.SW) puhaskasum (puhaskasum)?

Puhaskasum (netotulu) on 1147000.000.

Kui suur on ettevõtte koguvõlg?

Koguvõlg on 1079000.000.

Mis on tegevuskulude arv?

Tegevuskulud on 45314000.000.

Milline on ettevõtte rahaline näitaja?

Ettevõtte raha on 0.000.